Dr. Audrey E. Evans, emeritus professor of pediatrics at the University of Pennsylvania and the first chief of the Division of Oncology at the Children’s Hospital of Philadelphia, died peacefully at her home on Sept. 29, surrounded by loved ones. She was 97.
The Jack Martin Fund has built on its partnership with the Mount Sinai Health System to provide care and support to children with cancer through a $3.5 million gift to The Mount Sinai Hospital to establish the Jack Martin Fund Child and Adolescent Imaging Center at Mount Sinai Kravis Children’s Hospital.
University of Minnesota Medical School researchers explored the possible biological mechanisms that could explain the association between being overweight or obese prior to pregnancy and the increased risk of acute lymphoblastic leukemia in children.
FDA has approved Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors.
Foundation Medicine Inc., a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people with life-threatening diseases, has formed a collaboration to develop FoundationOne CDx as a companion diagnostic for Day One’s lead investigational therapy, DAY101 (tovorafenib).
FDA approved Imbruvica (ibrutinib) for pediatric patients 1 year of age or older with chronic graft versus host disease after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.
Following the first year of its 2022–27 strategic plan, St. Jude Children’s Research Hospital is increasing its investment in programs to advance the study and treatment of pediatric cancer and other catastrophic diseases (The Cancer Letter, May 14, 2021).
National Comprehensive Cancer Network published new NCCN Clinical Practice Guidelines in Oncology for pediatric central nervous system cancers.
Robert “Bob” Seeger, a leader in research for the fight against childhood cancer, died peacefully in Bend, OR, on June 4, at age 82.
Results from the ELIANA pivotal clinical trial showed the long-term benefit of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with a maximum survival follow-up of 5.9 years.
